(6S,7S,13E,16S,18R,19E,21R)-21-(乙酰氧基)-6,7,18-三羟基-16,18-二甲基-10-苯基-(11)松胞素-13,19-二烯-1-酮 | 108050-27-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 细胞松弛素类
• 中文名称: (6S,7S,13E,16S,18R,19E,21R)-21-(乙酰氧基)-6,7,18-三羟基-16,18-二甲基-10-苯基-(11)松胞素-13,19-二烯-1-酮
• 英文名称: cytochalasin P
• 英文别名: Cytochalasin Ppho；[(1R,2R,3E,5R,7S,9E,11R,12S,13S,14S,15R,16S)-16-benzyl-5,12,13-trihydroxy-5,7,13,14-tetramethyl-18-oxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl] acetate
• CAS: 108050-27-7
• 化学式: C₃₀H₄₁NO₆
• 分子量: 511.659
• InChiKey: AVASIWUXPVFFGK-WRERFMELSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (6S,7S,13E,16S,18R,19E,21R)-21-(乙酰氧基)-6,7,18-三羟基-16,18-二甲基-10-苯基-(11)松胞素-13,19-二烯-1-酮 在 sodium hydroxide 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 Cytochalasin Q_pho
  参考文献：
  名称：

  六个新的10-苯丙氨酸-[11]细胞松弛素，来自phomopsis SP的细胞松弛素N-S。

  摘要：

  从Phomopsis sp。（68-GO-164）6个名为细胞松弛素N，O，P，Q，R和S中分离新cytochalasans，与四个已知的化合物一起，epoxycytochalasins H和J和细胞松弛素H和J的结构（5 - 10）根据光谱数据，特别是1 H和13 C NMR，以及与已知化合物的化学相关性，确定了新化合物的10-苯基-[11]细胞松弛素。细胞松弛素P，Q，R和S（7 - 10）具有在分子中的环己烷部分新颖二醇型结构。

  DOI：

  10.1016/s0040-4020(01)83434-7
• 作为产物：
  描述：

  epoxycytochalasin H 、 三氟乙酸 生成 (6S,7S,13E,16S,18R,19E,21R)-21-(乙酰氧基)-6,7,18-三羟基-16,18-二甲基-10-苯基-(11)松胞素-13,19-二烯-1-酮
  参考文献：
  名称：

  IZAWA, YOSHIHIKO;HIROSE, TAKASHI;SHIMIZU, TAKAKO;KOYAMA, KIYOTAKA;NATORI,+, TETRAHEDRON, 45,(1989) N, C. 2323-2335

  摘要：

  DOI：

文献信息

• Three new 10-phenyl-(11)cytochalasans, cytochalasins N, O, and P from Phomopsis sp.
  作者：Takako Tomioka、Yoshihiko Izawa、Kiyotaka Koyama、Shinsaku Natori

  DOI：10.1248/cpb.35.902

  日期：——

  From Phomopsis sp. (68-GO-164) three new cytochalasans named cytochalasins N, O, and P were isolated, besides the four known cytochalasans, cytochalasins H and J and epoxycytochalasins H and J. The structures of the new compounds were determined by spectral analysis, especially by NMR, and by correlation reactions with known compounds.

  从Phomopsis sp.（68-GO-164）中分离出三种新的细胞质素，命名为细胞质素N、O和P，此外还有四种已知的细胞质素，即细胞质素H和J以及环氧细胞质素H和J。新化合物的结构通过光谱分析，特别是核磁共振（NMR）以及与已知化合物的相关反应确定。
• Intravascular stent with cytoskeletal inhibitors for the prevention of restenosis
  申请人：Boston Scientific Limited

  公开号：EP1512398A1

  公开（公告）日：2005-03-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Use of cytoskeletal inhibitors in crystalline form for the inhibition or prevention of restenosis
  申请人：BOSTON SCIENTIFIC SCIMED LIMITED

  公开号：EP2098230A1

  公开（公告）日：2009-09-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Therapeutic inhibitors of vascular smooth muscle cells
  申请人：Boston Scientific Limited

  公开号：EP2298310A2

  公开（公告）日：2011-03-23

  Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

  本发明提供了抑制哺乳动物宿主血管创伤或疾病后狭窄的方法，包括向宿主施用治疗有效剂量的治疗共轭物，该共轭物含有血管平滑肌结合蛋白，该蛋白以特定方式与血管平滑肌细胞的细胞表面结合，并与抑制肌肉细胞的细胞活性的治疗剂剂型耦合。还提供了向血管平滑肌细胞直接和/或靶向输送治疗剂的方法，这种方法通过抑制平滑肌细胞收缩，使血管腔扩张和固定，从而构成生物支架。
• Dosage form comprising taxol in crystalline form
  申请人：BOSTON SCIENTIFIC SCIMED LIMITED

  公开号：EP2292225A1

  公开（公告）日：2011-03-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。